LAURUSLABS1,942.50

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.05L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation384.6430.1480.1
+ Interest Income-5.6-15.2-6.6
+ Share-based Payments10.910.210.9
+ Unrealised FX (Gain) / Loss-8.8-1.9-25.9
+ Other Non-cash Items1.90.0-1.2
+ Other — Cash Effects are Investing / Financing0.0-57.17.5
Changes in Working Capital
+ Inventories-151.3-82.9-405.6
+ Trade Receivables — Current-85.1-405.0-181.0
+ Other Financial Assets — Non-current-88.5266.2312.6
+ Other Non-current Assets-38.5-55.024.8
+ Trade Payables — Current334.4-98.0274.3
+ Provisions — Current-0.00.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)236.4484.31,181.91,663.2
+ Total Adjustments (incl. Working Capital)354.0-8.4489.9
Cash from Operations (pre-tax)590.3475.91,671.7
+ Interest Paid — Operating-175.0-210.0-164.9
+ Other Inflows / (Outflows) — Operating4.953.480.8
+ Income Taxes Paid104.6137.5293.9
Cash from Operating Activities665.7601.71,623.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)678.3641.01,070.0
+ Disp of Fixed Assets2.399.96.8
+ Acq of Interests in Joint Ventures0.0105.449.0
+ Acq of Subsidiaries / Businesses (net)80.00.026.7
+ Disp of Subsidiaries / Businesses (net)-71.60.00.0
+ Interest Received — Investing5.66.26.6
+ Other Inflows / (Outflows) — Investing-0.4-41.443.6
Cash from Investing Activities-822.4-681.7-1,088.7
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options2.610.220.0
+ Proceeds from Borrowings757.7502.827.7
+ Repayment of Borrowings216.7315.7326.9
+ Payment of Lease Liabilities33.330.913.5
+ Interest Paid174.3209.2170.7
+ Dividends Paid86.243.186.3
+ Other Inflows / (Outflows) — Financing0.0125.325.0
Cash from Financing Activities249.839.3-524.7
Net Changes in Cash (pre-FX)93.1-40.810.1
+ Effect of FX Rate Changes on Cash0.21.43.0
Net Changes in Cash93.3-39.413.1
Closing Cash138.9
Reference Items
EBITDA777.51,055.31,777.72,416.0
EBITDA Margin %15.4219.0026.0927.33
Free Cash Flow (CFO − Capex)-12.6-39.4553.6553.6
Free Cash Flow to Equity-62.587.3
Free Cash Flow per Basic Share-0.23-0.7310.2510.25
Price to Free Cash Flow189.44
Cash Flow to Net Income4.101.681.82
Cash Paid for Taxes104.6137.5293.9
Cash Paid for Interest174.3209.2170.7
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.